These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 15015223)

  • 1. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
    Richardson MW; Grewal SS
    Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
    [No Abstract]   [Full Text] [Related]  

  • 3. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib and chronic-phase leukemias.
    Boros LG; Lee WN; Cascante M
    N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman JM; Melo JV
    N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
    Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
    Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ
    Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
    Imashuku S; Morimoto A; Kuriyama K; Kano G; Hibi S; Todo S
    Med Pediatr Oncol; 2003 Aug; 41(2):159-60. PubMed ID: 12825226
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 12. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the use of imatinib mesylate.
    Sawyers CL
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
    Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
    Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
    [No Abstract]   [Full Text] [Related]  

  • 17. [Imatinib--en epoch-making new drug against chronic myeloid leukemia].
    Lakartidningen; 2003 Jun; 100(26-27):2283. PubMed ID: 12872372
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
    Shah NP; Sawyers CL
    Curr Opin Investig Drugs; 2001 Mar; 2(3):422-3. PubMed ID: 11575716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.